Spironolactone and Insulin Resistance in Chronic Heart Failure (CHF)

Tottori University Hospital16 enrolled

Overview

The purpose of this study is to evaluate the effects of spironolactone and furosemide on insulin resistance in patients with chronic heart failure.

Diuretics is useful in CHF patients. On the other hand, they deteriorate glucose metabolism. Therefore, the purpose of this study is to evaluate the effects of spironolactone and furosemide on insulin resistance in patients with chronic heart failure.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Chronic Stable Heart Failure

Interventions

spironolactone + furosemideDRUG

spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16weeks

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * chronic stable heart failure Exclusion Criteria: * renal dysfunction or under treatment with antidiabetic agents

Outcomes

Primary Outcomes

insulin resistance

Time frame: 16 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.